MetLife, Inc.
NYSE:METInsurance - Life
-$0.15 today
- Market cap
- $62.71B
- Beta
- 0.78
- P/E (TTM)
- 15.4
- EPS (TTM)
- $5.55
- Dividend yield
- 2.68%
Volume 4.27M
Average 3.49M
MET EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
MetLife, Inc.NYSE: MET
EBITDA · Q2 FY2026 · quarter ended Jun 2026
EBITDA growth accelerates
Q2 FY2026 EBITDA of $1.33B rose 6.2% year over year, ahead of the -11.7% change in trailing-twelve-month EBITDA. Sequentially, it fell 25.1% from the prior quarter. Over 3 fiscal years it compounded at -6.7% a year.
Context
- EBITDA amounted to 8.4% of revenue in FY2025, down 2.1 pp from a year earlier.
- EBITDA increased in 1 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 6 analysts of $9.07B (+40.1%) for the fiscal year ending Dec 2026, a step up from the -12.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $1.33B-25.1% QoQ
- Last fiscal yearDec 2025
- $6.48B-12.2% YoY
- LTMJun 2026
- $5.96B-11.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +6.2% | +60.4% | +54.1 pp |
| 1 year | -12.2% | +40.1% | +52.3 pp |
| 3-year CAGR | -6.7% | +18.8% | +25.6 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 6.48B USD
- Year-over-year change
- -12.2%
- 4-year CAGR
- -10.6%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.48B | -12.2% |
| FY2024 | 2024-12-31 | 7.37B | +87.8% |
| FY2023 | 2023-12-31 | 3.93B | -50.8% |
| FY2022 | 2022-12-31 | 7.98B | -21.3% |
| FY2021 | 2021-12-31 | 10.13B | — |
EBITDA vs competitors
How MET compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -11.7% is the 7th highest of 11, against a peer median of -3.3%.
- EBITDA amounts to 7.6% of revenue for MET, versus a peer median of 16.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | CA$9.34B CAD | +24.5% | — | 16.1% | |
| LTM Jun 2026 | $7.11B USD | +122.7% | +4.5% | 39.3% | |
| LTM Jun 2026 | $5.96B USD | -11.7% | -6.7% | 7.6% | |
| LTM Jun 2026 | $5.28B USD | +120.4% | — | 8.1% | |
| LTM Jun 2026 | $3.16B USD | +104.5% | -8.9% | 16.3% | |
| LTM Jun 2026 | $1.26B USD | -43.8% | -14.8% | 9.5% | |
| LTM Jun 2026 | $948M USD | -5.1% | -24.7% | 25.2% | |
| LTM Sep 2026 | $946M USD | -27.8% | -49.6% | 17.4% | |
| LTM Jun 2026 | $901.1M USD | -1.6% | -11.2% | 19.4% | |
| LTM Sep 2026 | $785.19M USD | -20.6% | +9.3% | 22.7% | |
| LTM Sep 2026 | $596.82M USD | -61.8% | +10.1% | 9.5% | |
| Peer median (excluding MET) | — | -3.3% | -10.1% | 16.9% | |
Competitors are the stored peer set for MET. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 63.37B | 67.97B | 67.71B | 69.94B | 77.08B |
| Cost of Revenue | 46.53B | 49.03B | 50.42B | 50.94B | 49.06B |
| Gross Profit | 16.84B | 18.94B | 17.29B | 19B | 28.02B |
| Gross Margin | 26.6% | 27.9% | 25.5% | 27.2% | 36.4% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 5.76B | 5.86B | 6.18B | 5.99B | 0 |
| Operating Expenses | 8.32B | 12.57B | 15.13B | 13.38B | 23.36B |
| Depreciation & Amortization | 694M | 673M | 718M | 714M | 753M |
| EBITDA | 10.13B | 7.98B | 3.93B | 7.37B | 6.48B |
| EBITDA Margin | 16.0% | 11.7% | 5.8% | 10.5% | 8.4% |
| Operating Income | 8.52B | 6.36B | 2.16B | 5.62B | 4.66B |
| Operating Margin | 13.4% | 9.4% | 3.2% | 8.0% | 6.0% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 920M | 938M | 1.05B | 1.04B | 1.06B |
| Other Income / Expenses | 0 | 0 | 0 | 0 | 0 |
| Income Before Tax | 8.52B | 6.36B | 2.16B | 5.62B | 4.66B |
| Pre-Tax Margin | 13.4% | 9.4% | 3.2% | 8.0% | 6.0% |
| Income Tax Expense | 1.64B | 1.06B | 560M | 1.18B | 1.26B |
| Net Income | 6.86B | 5.28B | 1.58B | 4.43B | 3.38B |
| Net Margin | 10.8% | 7.8% | 2.3% | 6.3% | 4.4% |
| EPS (Basic) | 7.70 | 6.35 | 1.82 | 5.98 | 4.80 |
| EPS (Diluted) | 7.65 | 6.30 | 1.81 | 5.94 | 4.80 |
| Weighted Avg Shares | 825.54M | 779.1M | 762.43M | 689.21M | 664.96M |
| Weighted Avg Shares (Diluted) | 869.4M | 808.9M | 762.43M | 711.1M | 664.96M |
MetLife, Inc.
NYSE:MET
Intrinsic Alpha fair value
Locked
Current Price
$99.79
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.